Olfr800 is a member of the olfactory receptor family, which are G protein-coupled receptors (GPCRs) crucial for the detection of odorants. These receptors, including Olfr800, are key components in the olfactory system, responsible for initiating the olfactory signal transduction pathway. The activation of olfactory receptors generally occurs through the binding of specific odorant molecules, causing conformational changes in the receptor. These changes enable interaction with G proteins, initiating a series of intracellular signaling events that ultimately lead to the perception of smell. The specific ligands and broader physiological functions of Olfr800, like many olfactory receptors, are not fully characterized, reflecting the diversity and specificity inherent in olfactory receptor-ligand interactions. The activation mechanisms of Olfr800 are influenced by various factors within the cellular environment. A significant pathway regulating GPCR function is the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP, a secondary messenger, plays a crucial role in numerous cellular processes, including GPCR signaling. The production of cAMP is catalyzed by adenylate cyclase, which converts ATP into cAMP in response to external stimuli. The resultant cAMP activates protein kinase A (PKA), leading to the phosphorylation of different target proteins, including GPCRs. This phosphorylation can modulate the receptor's sensitivity to its ligands, affecting its activation dynamics.
Phosphodiesterases (PDEs), responsible for the degradation of cAMP, play a vital role in regulating its intracellular levels. Inhibiting PDEs leads to an increase in cAMP within the cell, indirectly affecting GPCR signaling. This increase in cAMP, due to PDE inhibition, can indirectly modulate the activity of Olfr800 through various mechanisms, including changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Moreover, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly influence the activity of Olfr800. In summary, understanding the activation of Olfr800 is essential for comprehending the olfactory system and the broader role of GPCRs in physiological and sensory processes. The complex interplay between different cellular components and signaling molecules, as well as the potential for modulation by external compounds, highlights the complexity and importance of these receptors in sensory perception and cellular communication.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, derived from Coleus forskohlii, activates adenylate cyclase, increasing cAMP levels. This rise in cAMP may influence GPCR signaling, potentially affecting Olfr800 activity by modulating receptor phosphorylation and sensitivity via PKA-mediated pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, elevates intracellular cAMP through adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr800 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels, potentially influencing Olfr800 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine stimulates α and β-adrenergic receptors, boosting cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr800 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, leads to increased cAMP levels. Elevated cAMP may enhance Olfr800 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr800 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $92.00 $138.00 | ||
Salbutamol, a β2-adrenergic agonist, raises cAMP levels via adenylate cyclase activation. This increase might boost Olfr800 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $31.00 $83.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr800 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr800 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr800 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. | ||||||